Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Bevacizumab + Pemetrexed + Cisplatin for Unresectable Malignant Peritoneal Mesothelioma (Phase II, Single Arm)
ChiCTR2500108786Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, bevacizumab, pemetrexed and cisplatin in peritoneal mesothelioma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: progression-free survival. Started Sep 2025; status: recruiting.
02
Drugs
sintilimabbevacizumabpemetrexedcisplatin
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on ChiCTR2500108786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108786.